CEL-SCI Corp
AMEX:CVM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CEL-SCI Corp
Operating Income
CEL-SCI Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CEL-SCI Corp
AMEX:CVM
|
Operating Income
-$23.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$11.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$16.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$3.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
12%
|
|
CEL-SCI Corp
Glance View
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.
See Also
What is CEL-SCI Corp's Operating Income?
Operating Income
-23.3m
USD
Based on the financial report for Dec 31, 2025, CEL-SCI Corp's Operating Income amounts to -23.3m USD.
What is CEL-SCI Corp's Operating Income growth rate?
Operating Income CAGR 10Y
2%
Over the last year, the Operating Income growth was 13%. The average annual Operating Income growth rates for CEL-SCI Corp have been 13% over the past three years , 6% over the past five years , and 2% over the past ten years .
